Previous 10 | Next 10 |
2024-03-06 12:50:02 ET Gainers: Aptorum Group Ltd ( APM ) +736% . BiomX ( PHGE ) +144% . Trxade Health ( MEDS ) +87% . New Horizon Aircraft Ltd ( HOVR ) +69% . Rail Vision Ltd ( RVSN ) +62% . Airship AI Holdings ( AISP ) ...
2024-03-06 12:03:05 ET Wave Life Sciences Ltd. (WVE) Q4 2023 Earnings Call Transcript March 06, 2024 08:30 AM ET Company Participants Kate Rausch - Vice President, Investor Relations & Corporate Affairs Paul Bolno - President & Chief Executive Officer Ann...
2024-03-06 07:34:03 ET More on Wave Life Sciences Wave Life Sciences: What To Make Of The Discounted Offering Wave Life Sciences Q4 2023 Earnings Preview Mizuho says market 'doesn't understand' Wave capital raise Seeking Alpha’s Quant Rating on Wave Li...
INHBE lead clinical candidate selected; potential best-in-class treatment for obesity with potent and durable silencing, weight loss with no loss of muscle mass, reduction of visceral fat, and every-six-month or annual subcutaneous dosing; clinical trial initiation expected 1Q 2025 Dose...
Klepierre (KLPEF) is expected to report for Q4 2023 comScore Inc. (SCOR) is expected to report $0.8 for Q4 2023 Universal Stainless & Alloy Products Inc. (USAP) is expected to report for Q4 2023 FAT Brands Inc. (FAT) is expected to report $-1.55 for Q4 2023 Jet.AI Inc. (JTAI) ...
2024-03-05 13:41:27 ET More on Wave Life Sciences Wave Life Sciences: What To Make Of The Discounted Offering Mizuho says market 'doesn't understand' Wave capital raise Wave Life Sciences falls sharply on pricing $100M secondary offering Seeking Alpha’...
CAMBRIDGE, Mass., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, will host a live webcast and conference call at 8:30 a.m. ET on Wednesday, March 6...
Presentations include data for WVE-N531 that provide first clinical evidence of a potential therapeutic for DMD accessing satellite cells, which are important for potential muscle regeneration Presentations also include non-human primate data demonstrating significant concentrations of ...
2024-01-30 17:31:21 ET Gainers: NKGen Biotech ( NKGN ) +37% . Powell Industries ( POWL ) +15% . Manhattan Associates ( MANH ) +4% . WAVE Life Sciences ( WVE ) +4% . Arbutus Biopharma Corporation ( ABUS ) +3% . Losers:...
Multiple data catalysts across all clinical programs expected throughout 2024, including data for WVE-006 in AATD which would provide first-ever RNA editing proof-of-mechanism in humans Selection of clinical candidate for GalNAc-siRNA INHBE program in obesity now planned for 3Q 2024, ah...
News, Short Squeeze, Breakout and More Instantly...
Wave Life Sciences Ltd. Company Name:
WVE Stock Symbol:
NASDAQ Market:
CAMBRIDGE, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, will host a live webcast and conference call at 8:30 a.m. ET on Thursday, May 9, 20...
CAMBRIDGE, Mass., April 30, 2024 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced the approval of its first clinical trial application (CTA) for it...
GSK has selected the first two programs to advance following achievement of target validation, marking transition to next phase of research collab...